321 related articles for article (PubMed ID: 31165208)
1. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides: A primer.
Scoles DR; Minikel EV; Pulst SM
Neurol Genet; 2019 Apr; 5(2):e323. PubMed ID: 31119194
[TBL] [Abstract][Full Text] [Related]
3. [Gene-specific treatment approaches in muscle diseases].
Lehmann Urban D; Schneider I
Nervenarzt; 2020 Apr; 91(4):318-323. PubMed ID: 32076754
[TBL] [Abstract][Full Text] [Related]
4. Oligonucleotide therapeutics in neurodegenerative diseases.
Scoles DR; Pulst SM
RNA Biol; 2018; 15(6):707-714. PubMed ID: 29560813
[TBL] [Abstract][Full Text] [Related]
5. Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.
Li D; Mastaglia FL; Fletcher S; Wilton SD
Trends Pharmacol Sci; 2018 Nov; 39(11):982-994. PubMed ID: 30282590
[TBL] [Abstract][Full Text] [Related]
6. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
7. ASO Therapy: Hope for Genetic Neurological Diseases.
Muth CC
JAMA; 2018 Feb; 319(7):644-646. PubMed ID: 29383373
[No Abstract] [Full Text] [Related]
8. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
9. Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.
Cantara S; Simoncelli G; Ricci C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732027
[TBL] [Abstract][Full Text] [Related]
10. Antisense therapies in neurological diseases.
Brunet de Courssou JB; Durr A; Adams D; Corvol JC; Mariani LL
Brain; 2022 Apr; 145(3):816-831. PubMed ID: 35286370
[TBL] [Abstract][Full Text] [Related]
11. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
Barresi V; Musmeci C; Rinaldi A; Condorelli DF
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
[TBL] [Abstract][Full Text] [Related]
12. Antisense therapies for movement disorders.
Scoles DR; Pulst SM
Mov Disord; 2019 Aug; 34(8):1112-1119. PubMed ID: 31283857
[TBL] [Abstract][Full Text] [Related]
13. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
Bennett CF; Krainer AR; Cleveland DW
Annu Rev Neurosci; 2019 Jul; 42():385-406. PubMed ID: 31283897
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic antisense oligonucleotides for movement disorders.
Doxakis E
Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
[TBL] [Abstract][Full Text] [Related]
15. A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey.
Oberemok VV; Laikova KV; Repetskaya AI; Kenyo IM; Gorlov MV; Kasich IN; Krasnodubets AM; Gal'chinsky NV; Fomochkina II; Zaitsev AS; Bekirova VV; Seidosmanova EE; Dydik KI; Meshcheryakova AO; Nazarov SA; Smagliy NN; Chelengerova EL; Kulanova AA; Deri K; Subbotkin MV; Useinov RZ; Shumskykh MN; Kubyshkin AV
Molecules; 2018 May; 23(6):. PubMed ID: 29844255
[TBL] [Abstract][Full Text] [Related]
16. Translational development of splice-modifying antisense oligomers.
Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
[TBL] [Abstract][Full Text] [Related]
17. Antisense Oligonucleotides for the Study and Treatment of ALS.
Boros BD; Schoch KM; Kreple CJ; Miller TM
Neurotherapeutics; 2022 Jul; 19(4):1145-1158. PubMed ID: 35653060
[TBL] [Abstract][Full Text] [Related]
18. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
19. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis.
Ly CV; Miller TM
Curr Opin Neurol; 2018 Oct; 31(5):648-654. PubMed ID: 30028737
[TBL] [Abstract][Full Text] [Related]
20. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]